FoxO-04 DRI 10mg

FOXO4-DRI 10mg — Senolytic Research Peptide for Cellular Senescence Studies

FOXO4-DRI (FOXO4 D-Retro-Inverso) is a 46-amino-acid synthetic peptide engineered using D-amino acids in reverse sequence, a strategy that confers exceptional resistance to enzymatic degradation while preserving the peptide’s interaction with its target proteins. FOXO4-DRI was designed specifically as a research tool for studying senolytic mechanisms — the selective elimination of senescent cells — making it one of the most innovative compounds in the anti-aging peptides research category.

Cellular Senescence and Aging

Cellular senescence is a state of permanent cell cycle arrest accompanied by characteristic changes in gene expression, secretion of inflammatory factors known as the senescence-associated secretory phenotype (SASP), and resistance to apoptosis. Senescent cells accumulate with age and contribute to numerous age-related pathologies, making them important targets in aging research. FOXO4-DRI provides researchers with a tool for investigating senescent cell biology and senolytic strategies.

FOXO4-p53 Interaction Mechanism

FOXO4-DRI’s research mechanism involves disruption of the FOXO4-p53 protein-protein interaction that maintains senescent cell viability. In senescent cells, FOXO4 sequesters p53 in the nucleus, preventing it from triggering apoptosis. FOXO4-DRI competitively binds FOXO4, releasing p53 to execute apoptosis in senescent cells while leaving normal cells largely unaffected. This selective mechanism is the foundation of FOXO4-DRI’s research utility.

Senolytic Research Applications

FOXO4-DRI has become a widely used research tool for investigating senolytic strategies in cellular and animal models. Studies have documented selective elimination of senescent cells in tissues with high senescent cell burden, reduction of SASP markers, and improvements in tissue function in aged animal models. These findings have generated substantial interest in senolytic approaches to age-related disease research.

Tissue Function and Aging Research

Research using FOXO4-DRI has examined improvements in tissue function in animal models of aging. Studies have documented effects on hair follicle function, renal function biomarkers, exercise capacity, and other parameters of tissue health that decline with age, providing evidence that senescent cell elimination through FOXO4-DRI can reverse some aspects of aging-related decline in research models.

D-Retro-Inverso Stability

The D-retro-inverso modification gives FOXO4-DRI exceptional stability against proteolytic degradation while preserving the three-dimensional structure needed for FOXO4 interaction. This engineering approach demonstrates how protein-protein interactions can be selectively disrupted using stabilized peptide research tools, an approach that has informed peptide engineering more broadly.

Comparison With Related Anti-Aging Compounds

FOXO4-DRI is frequently studied alongside other longevity-focused peptides such as Epithalon, Humanin, and mitochondrial-derived peptides like MOTS-c. Parallel investigations help distinguish senolytic mechanisms from telomere-related and mitochondrial pathways in aging research.

Quality, Storage, and Compliance

Each vial of FOXO4-DRI 10mg is manufactured to 99%+ HPLC-verified purity and supplied as a sterile lyophilized powder. Store unreconstituted vials at -20°C; reconstituted material should be refrigerated at 2–8°C and used promptly. This FOXO4-DRI product is sold strictly for in-vitro laboratory research only — not for human consumption, diagnostic use, or any clinical application. Buyers must comply with all applicable provincial and federal regulations.